C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

C4 Therapeutics, Inc.NASDAQ: CCCC

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $24.61M fell 9.1% year over year, ahead of the -11.6% change in trailing-twelve-month research & development. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Research & development amounted to 290.0% of revenue in FY2025, down 20.9 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -9.1% holds above the trailing-twelve-month pace of -11.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.61M-1.5% QoQ
Last fiscal yearDec 2025
$104.24M-5.8% YoY
LTMMar 2026
$101.77M-11.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.1%——
1 year-5.8%——
3-year CAGR-4.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
104.24M USD
Year-over-year change
-5.8%
4-year CAGR
+2.4%

Research & Development vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.6% is the 6th highest of 9, against a peer median of -1.1%.
  • Research & development amounts to 291.9% of revenue for CCCC, versus a peer median of 576.3%.
CCCC Competitors
Research & Development for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M USD+11.4%-23.3%327.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M USD-11.6%-4.0%291.9%
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
CDXSCodexis, Inc.LTM Mar 2026$47.7M USD-0.5%-13.2%61.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
OABIOmniAb, Inc.LTM Mar 2026$44.75M USD-15.8%-0.4%154.8%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$24.4M USD-23.4%-12.2%824.8%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M USD+68.3%+29.6%902.4%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding CCCC) —-1.1%-9.8%576.3%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.79M31.1M20.76M35.58M35.95M
Cost of Revenue007.74M07.98M
Gross Profit45.79M31.1M13.02M35.58M27.97M
Gross Margin100.0%100.0%62.7%100.0%77.8%
Research & Development94.67M117.84M117.71M110.64M104.24M
Selling, General & Admin33.25M42.79M42.08M42.12M36.2M
Operating Expenses127.92M160.63M152.05M155.2M132.46M
Depreciation & Amortization1.49M1.68M7.74M1.82M1.96M
EBITDA(80.26M)(124.28M)(122.1M)(103.37M)(102.91M)
EBITDA Margin-175.3%-399.7%-588.3%-290.5%-286.3%
Operating Income(82.13M)(129.53M)(139.03M)(119.61M)(104.49M)
Operating Margin-179.4%-416.6%-669.8%-336.1%-290.7%
Interest Income387K3.58M9.81M14.43M10.35M
Interest Expense2.15M2.22M1.37M00
Other Income / Expenses(1.76M)1.36M7.82M14.43M(384K)
Income Before Tax(83.89M)(128.18M)(131.21M)(105.19M)(104.87M)
Pre-Tax Margin-183.2%-412.2%-632.2%-295.6%-291.7%
Income Tax Expense001.28M131K121K
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Net Margin-183.2%-412.2%-638.3%-296.0%-292.1%
EPS (Basic)(1.82)(2.62)(2.67)(1.52)(1.27)
EPS (Diluted)(1.82)(2.62)(2.67)(1.52)(1.27)
Weighted Avg Shares46.04M48.86M49.64M69.37M82.89M
Weighted Avg Shares (Diluted)46.04M48.86M49.64M69.37M82.89M

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.